论文部分内容阅读
针对肿瘤干细胞进行靶向治疗是遏止肿瘤复发和转移的关键。表观遗传学在干细胞发育及体细胞重编程中的重要作用提示其可能在肿瘤干细胞的发生发展中发挥作用。表观基因组包含DNA甲基化、组蛋白修饰、染色体重塑和非编码RNA调控的基因表达模式,在肾癌细胞中有多种表观基因组的异常改变。目前已成功的从肾细胞癌中获得SP细胞、细胞囊球和CD105+细胞等具肿瘤干细胞属性的细胞亚群。随着对肾细胞癌(renal cell carcinoma,RCC)遗传研究的不断深入,发现DNA序列以外的调控机制异常在肿瘤的发生发展过程中起重要的作用。对肾癌发生相关的表观遗传学的认识有助于推进新的治疗方式,而对发现新的预后和早期诊断标志将起更重要的作用。本文对目前肾癌干细胞和表观遗传学相关领域的最新研究,特别是肾癌干细胞发生和发展过程中表观遗传学可能的调控作用及机制进行综述。
Targeted treatment of cancer stem cells is the key to halting tumor recurrence and metastasis. The important role of epigenetics in stem cell development and somatic cell reprogramming suggests that it may play a role in the development of cancer stem cells. The epigenome contains gene expression patterns of DNA methylation, histone modification, chromosomal remodeling and non-coding RNA regulation, and there are many abnormal changes in the apparent genome in renal cancer cells. Currently has been obtained from renal cell carcinoma of the SP cells, cystic globular and CD105 + cells with tumor stem cell properties such as cell subsets. With the deepening of genetic research on renal cell carcinoma (RCC), it is found that abnormalities of regulatory mechanisms other than DNA sequences play an important role in tumorigenesis and development. Epigenetics, which is associated with the development of renal cell carcinoma, helps to advance new therapies and plays a more important role in finding new prognostic and early diagnostic markers. This review summarizes recent advances in current renal cell carcinoma and epigenetics related fields, and in particular the possible regulatory roles of epigenetics in renal cell carcinoma stem cell development and progression.